GSK/Corixa Bexxar user fee extended
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA extends the review period for GlaxoSmithKline/Corixa's Bexxar by three months, to Aug. 1, to review additional safety data. Corixa submitted safety data in early April from an additional 375 non-Hodgkin's lymphoma patients. The data was requested by FDA after the Dec. 17 Oncologic Drugs Advisory Committee review of the tositumomab BLA. "The overall safety profile of Bexxar was not altered by the inclusion of this additional data," Corixa maintains. "A majority of the steps required for approval already have been completed," the firm notes, including satisfactory pre-approval manufacturing inspections, "agreement on several elements of post approval studies," submission of secondary draft labeling, and "completion and submission of information and procedures for drug ordering, dose preparation, dosimetry methods and dose administration." The companies remain in discussion with FDA regarding labeling and postmarketing commitment
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.